Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610507 | 0.91 | RAB9A (0.49) | POLBRAB9AMEN1KMT2AEPHX2 | |
| SCHEMBL3600618 | 0.84 | KCNJ11 (0.43) | RAB9AKMT2AEPHX2NPC1ALDH1A1 | |
| SCHEMBL2437836 | 0.80 | RAB9A (0.48) | POLBRAB9AMEN1KMT2AEPHX2 | |
| SCHEMBL3608532 | 0.73 | L3MBTL1 (0.53) | POLBMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL30824627 | 0.73 | L3MBTL1 (0.50) | POLBRAB9AMEN1KMT2AEPHX2 | |
| SCHEMBL2437885 | 0.73 | L3MBTL1 (0.50) | POLBRAB9AMEN1KMT2AEPHX2 | |
| SCHEMBL2436291 | 0.72 | RAB9A (0.60) | RAB9AMEN1KMT2AEPHX2NPC1 | |
| SCHEMBL3598832 | 0.72 | RAB9A (0.53) | RAB9AMEN1KMT2AEPHX2TSHR | |
| SCHEMBL3608727 | 0.72 | RAB9A (0.59) | RAB9AMEN1KMT2AEPHX2NPC1 | |
| SCHEMBL11650801 | 0.72 | ALDH1A1 (0.52) | RAB9AMEN1KMT2ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299075-B2 | Substituted thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2012-10-30 | — | — | US | disclosed |
| CN-102516204-A | Substituted morpholine and thiomorpholine derivatives | LUNDBECK & CO AS H | 2012-06-27 | — | — | CN | disclosed |
| US-20110294787-A1 | SUBSTITUTED THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2011-12-01 | — | — | US | disclosed |
| US-8012962-B2 | Substituted thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2011-09-06 | — | — | US | disclosed |
| US-7812023-B2 | Methods of using substituted morpholine derivatives | H. LUNDBECK A/S (DK) | 2010-10-12 | — | — | US | disclosed |
| US-20100063033-A1 | Methods of using substituted morpholine derivatives | H. LUNDBECK A/S (DK) | 2010-03-11 | — | — | US | disclosed |
| US-20100063036-A1 | Substituted morpholine and thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2010-03-11 | — | — | US | disclosed |
| EP-1947093-B9 | Substituted morpholine and thiomorpholine derivatives | LUNDBECK & CO AS H (DK) | 2010-03-03 | — | — | EP | disclosed |
| EP-2138487-A1 | Substituted morpholine and thiomorpholine derivatives for the treatment of bipolar disorders | H. Lundbeck A/S (DK) | 2009-12-30 | — | — | EP | disclosed |
| US-7632835-B2 | 2-Cyclopentyl-N-(2-bromo-6-trifluoromethyl-4-(thio)morpholin-4-yl-phenyl)-acetamide; potent openers of the KCNQ family of potassium ion channels; antiepileptic agents; anticonvulsants; anxiolytic agents; neurodegenerative disorders; analgesics for headaches, neuropathic pain; bipolar disorders | H. LUNDBECK A/S (DK) | 2009-12-15 | — | — | US | disclosed |
| US-20090143369-A1 | METHODS OF USING SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090137571-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| US-7501414-B2 | Substituted morpholine and thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2009-03-10 | — | — | US | disclosed |
| EP-1727809-B8 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2008-10-29 | — | — | EP | disclosed |
| EP-1947093-A1 | Substituted morpholine and thiomorpholine derivatives | H. Lundbeck A/S (DK) | 2008-07-23 | — | — | EP | disclosed |
| EP-1727809-B1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2008-06-11 | — | — | EP | disclosed |
| CN-1930138-A | Substituted morpholine and thiomorpholine derivatives | LUNDBECK & CO AS H (DK) | 2007-03-14 | — | — | CN | disclosed |
| EP-1727809-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H.Lundbeck A/S (DK) | 2006-12-06 | — | — | EP | disclosed |
| US-20060167248-A1 | Substituted morpholine and thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| WO-2005087754-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167248-A1 | Substituted morpholine and thiomorpholine derivatives | OPRM1, OPRK1, OPRD1 | POLB 4348/4885RAB9A 1246/4885MEN1 1899/4885 |
| US-20100063033-A1 | Methods of using substituted morpholine derivatives | OPRM1, TPMT, SIGMAR1 | POLB 3796/4885RAB9A 1770/4885MEN1 1506/4885 |
| US-20090137571-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | OPRM1, OPRK1, OPRD1 | POLB 4295/4885RAB9A 1275/4885MEN1 1883/4885 |
| US-20090143369-A1 | METHODS OF USING SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | OPRM1, TPMT, OPRK1 | POLB 3915/4885RAB9A 1738/4885MEN1 1222/4885 |
| US-20110294787-A1 | SUBSTITUTED THIOMORPHOLINE DERIVATIVES | OPRM1, OPRK1, OPRL1 | POLB 4727/4885RAB9A 1579/4885MEN1 2499/4885 |
| US-20100063036-A1 | Substituted morpholine and thiomorpholine derivatives | OPRM1, OPRK1, OPRD1 | POLB 4348/4885RAB9A 1246/4885MEN1 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.